Fig. 2
From: Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia
Pharmacologic targeting of PSMB8 confirms immunoproteasome requirement in KMT2A-r AML. A Relative cell number and percentage of dead cells (SYTOX®Blue+) of human leukemic cell lines as indicated after treatment with PR-957 (50 nM, 100 nM) for 96 h or DMSO as diluent control. n = 4 independent experiments, in triplicate; mean with SEM; paired Student t test. B Kaplan–Meier survival curves for two patient derived xenografts (PDX) using 1–5 × 104 cells from patient samples containing an KMT2A::MLLT3 (upper) or KMT2A::AFF1 (lower) translocation injected into NSGW41 recipient mice. Recipients treated in vivo with 3-6 mg/kg PR-957 for 5 days/week or NaCl 0.9% as diluent control on 4 alternate weeks (n = 7 per group for KMT2A::MLLT3; n = 8 for KMT2A::AFF1). Two independent cohorts; Mantel-Cox test